Pancragen

Overview

A short synthetic peptide bioregulator (Lys-Glu-Asp-Trp) from the Khavinson family, marketed for pancreatic/metabolic support. Evidence is largely Russian-language and preclinical.

Mechanism of Action

Proposed tissue-specific peptide-bioregulator activity in pancreatic tissue; not established by independent research.

Research Summary

Primarily Russian institutional studies; no large independent controlled human trials.

Vendors selling Pancragen

Scored vendors carrying Pancragen, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• Not well characterized

Frequently asked questions

Has Pancragen been independently lab-tested?

Disclosed Labs has collected 7 Certificates of Analysis (COA) for Pancragen from 5 independent testing labs. 4 vendors have submitted material for testing. Products average 99.4% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/pancragen/testing.

What is the average purity of Pancragen on the market?

Based on 7 COAs analyzed by Disclosed Labs, Pancragen products average 99.4% (±0.6%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/pancragen/coas.

Where can researchers source Pancragen?

3 vendors with Disclosed Labs trust grades currently list Pancragen, including Peptidology, BioLongevity Labs, Certified Peptides. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/pancragen.

How does Pancragen work?

Proposed tissue-specific peptide-bioregulator activity in pancreatic tissue; not established by independent research.

What does the research say about Pancragen?

Primarily Russian institutional studies; no large independent controlled human trials.